{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:11:56Z","timestamp":1790370716118,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T00:00:00Z","timestamp":1541548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00066-018-1395-y","type":"journal-article","created":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T09:00:48Z","timestamp":1541581248000},"page":"393-401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a\u00a0randomized controlled trial","Patienten- versus arztberichtete Ergebnisse von Prostatakrebspatienten nach hypofraktionierter Radiotherapie innerhalb einer randomisierten kontrollierten Studie"],"prefix":"10.1007","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6130-2502","authenticated-orcid":false,"given":"Elke","family":"Rammant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Swimberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Vanderstraeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas","family":"Lumen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Decaestecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e","family":"Bultijnck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"De Meerleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Sarrazyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roos","family":"Colman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Fonteyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,7]]},"reference":[{"issue":"4","key":"1395_CR1","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618\u2013629","journal-title":"Eur Urol"},{"issue":"2","key":"1395_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0360-3016(82)90517-X","volume":"8","author":"HD Thames","year":"1982","unstructured":"Thames HD, Withers HR, Peters LJ, Fletcher GH (1982) Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 8(2):219\u2013226","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1395_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ijrobp.2012.03.004","volume":"85","author":"IR Vogelius","year":"2013","unstructured":"Vogelius IR, Bentzen SM (2013) Meta-analysis of the alpha\/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys 85(1):89\u201394","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1395_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12430","author":"A Zempl\u00e9nyi","year":"2016","unstructured":"Zempl\u00e9nyi A, Kal\u00f3 Z, Kov\u00e1cs G, Farkas R, Be\u00f6the T, B\u00e1nyai D et al (2016) Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer. Eur J Cancer Care (Engl). \n                    https:\/\/doi.org\/10.1111\/ecc.12430","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"1","key":"1395_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(11)70293-5","volume":"13","author":"D Dearnaley","year":"2012","unstructured":"Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C et al (2012) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 13(1):43\u201354","journal-title":"Lancet Oncol"},{"key":"1395_CR6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.71.7397","author":"CN Catton","year":"2017","unstructured":"Catton CN, Lukka H, Gu C\u2011S, Martin JM, Supiot S, Chung PW et al (2017) Randomized trial of a\u00a0hypofractionated radiation regimen for the treatment of localized prostate cancer. J\u00a0Clin Oncol. \n                    https:\/\/doi.org\/10.1200\/jco.2016.71.7397","journal-title":"J Clin Oncol"},{"issue":"20","key":"1395_CR7","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP et al (2016) Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J\u00a0Clin Oncol 34(20):2325\u20132332","journal-title":"J Clin Oncol"},{"key":"1395_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.70.4189","author":"G Arcangeli","year":"2017","unstructured":"Arcangeli G, Saracino B, Arcangeli S, Gomellini S, Petrongari MG, Sanguineti G et al (2017) Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a\u00a0phase III randomized trial. J\u00a0Clin Oncol. \n                    https:\/\/doi.org\/10.1200\/jco.2016.70.4189","journal-title":"J Clin Oncol"},{"issue":"8","key":"1395_CR9","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5\u2011year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17(8):1047\u20131060. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(16)30102-4","journal-title":"Lancet Oncol"},{"issue":"4","key":"1395_CR10","first-page":"119","volume":"5","author":"LT Flores","year":"2012","unstructured":"Flores LT, Bennett AV, Law EB, Hajj C, Griffith MP, Goodman KA (2012) Patient-reported outcomes vs. clinician symptom reporting during chemoradiation for rectal cancer. Gastrointest Cancer Res 5(4):119","journal-title":"Gastrointest Cancer Res"},{"issue":"8","key":"1395_CR11","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","volume":"33","author":"M Maio Di","year":"2015","unstructured":"Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F et\u00a0al (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J\u00a0Clin Oncol 33(8):910\u2013915","journal-title":"J Clin Oncol"},{"issue":"17","key":"1395_CR12","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1200\/JCO.2004.03.025","volume":"22","author":"EK Fromme","year":"2004","unstructured":"Fromme EK, Eilers KM, Mori M, Hsieh Y\u2011C, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J\u00a0Clin Oncol 22(17):3485\u20133490","journal-title":"J Clin Oncol"},{"issue":"3","key":"1395_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S1470-2045(14)70482-6","volume":"16","author":"S Aluwini","year":"2015","unstructured":"Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP et al (2015) Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a\u00a0randomised non-inferiority phase 3 trial. Lancet Oncol 16(3):274\u2013283","journal-title":"Lancet Oncol"},{"issue":"16","key":"1395_CR14","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/S1470-2045(15)00280-6","volume":"16","author":"A Wilkins","year":"2015","unstructured":"Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C et al (2015) Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2\u2011year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 16(16):1605\u20131616","journal-title":"Lancet Oncol"},{"key":"1395_CR15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/1748-717X-8-206","volume":"8","author":"D Norkus","year":"2013","unstructured":"Norkus D, Karklelyte A, Engels B, Versmessen H, Griskevicius R, De Ridder M et\u00a0al (2013) A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients. Radiat Oncol 8:206. \n                    https:\/\/doi.org\/10.1186\/1748-717x-8-206","journal-title":"Radiat Oncol"},{"key":"1395_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.12.016","author":"V Fonteyne","year":"2018","unstructured":"Fonteyne V, Sarrazyn C, Swimberghe M, De Meerleer G, Rammant E, Vanderstraeten B et al (2018) Four-weeks versus 5\u2011weeks hypofractionated high dose radiotherapy as primary therapy for prostate cancer: interim safety analysis of a\u00a0randomized phase 3 trial. Int J Radiat Oncol Biol Phys. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2017.12.016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"8","key":"1395_CR17","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/jama.2013.879","volume":"309","author":"M Calvert","year":"2013","unstructured":"Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD et al (2013) Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309(8):814\u2013822","journal-title":"JAMA"},{"issue":"5","key":"1395_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a\u00a0quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365\u2013376","journal-title":"J. Natl. Cancer Inst."},{"issue":"16","key":"1395_CR19","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1016\/j.ejca.2008.07.030","volume":"44","author":"G Andel van","year":"2008","unstructured":"van Andel G, Bottomley A, Foss\u00e5 SD, Efficace F, Coens C, Guerif S et al (2008) An international field study of the EORTC QLQ-PR25: a\u00a0questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 44(16):2418\u20132424","journal-title":"Eur J Cancer"},{"key":"1395_CR20","volume-title":"Statistical methods for rates and proportions","author":"JL Fleiss","year":"2013","unstructured":"Fleiss JL, Levin B, Paik MC (2013) Statistical methods for rates and proportions. John Wiley & Sons, New Jersey"},{"issue":"3","key":"1395_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.radonc.2006.05.004","volume":"79","author":"H Geinitz","year":"2006","unstructured":"Geinitz H, Zimmermann FB, Thamm R, Erber C, M\u00fcller T, Keller M et\u00a0al (2006) Late rectal symptoms and quality of life after conformal radiation therapy for prostate cancer. Radiother Oncol 79(3):341\u2013347","journal-title":"Radiother Oncol"},{"issue":"3","key":"1395_CR22","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/cncr.10248","volume":"94","author":"CG Bacon","year":"2002","unstructured":"Bacon CG, Giovannucci E, Testa M, Glass TA, Kawachi I (2002) The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer 94(3):862\u2013871","journal-title":"Cancer"},{"issue":"5","key":"1395_CR23","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s12094-017-1749-4","volume":"20","author":"M Bonet","year":"2018","unstructured":"Bonet M, Cayetano L, N\u00fa\u00f1ez M, Jovell-Fern\u00e1ndez E, Aguilar A, Ribas Y (2018) Assessment of acute bowel function after radiotherapy for prostate cancer: Is it accurate enough? Clin Transl Oncol 20(5):576\u2013583","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"1395_CR24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.radonc.2013.11.011","volume":"110","author":"W Schaake","year":"2014","unstructured":"Schaake W, Wiegman EM, de Groot M, van der Laan HP, van der Schans CP, van den Bergh AC et\u00a0al (2014) The impact of gastrointestinal and genitourinary toxicity on health related quality of life among irradiated prostate cancer patients. Radiother Oncol 110(2):284\u2013290","journal-title":"Radiother Oncol"},{"issue":"15","key":"1395_CR25","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","volume":"375","author":"JL Donovan","year":"2016","unstructured":"Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E et al (2016) Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. New Engl J Med 375(15):1425\u20131437","journal-title":"New Engl J Med"},{"issue":"11","key":"1395_CR26","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1001\/jama.2017.1704","volume":"317","author":"DA Barocas","year":"2017","unstructured":"Barocas DA, Alvarez J, Resnick MJ, Koyama T, Hoffman KE, Tyson MD et al (2017) Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years. JAMA 317(11):1126\u20131140","journal-title":"JAMA"},{"key":"1395_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7156","author":"E Basch","year":"2017","unstructured":"Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C et al (2017) Overall survival results of a\u00a0trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. \n                    https:\/\/doi.org\/10.1001\/jama.2017.7156","journal-title":"JAMA"},{"issue":"6","key":"1395_CR28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","volume":"34","author":"E Basch","year":"2015","unstructured":"Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P et al (2015) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a\u00a0randomized controlled trial. J\u00a0Clin Oncol 34(6):557\u2013565","journal-title":"J Clin Oncol"},{"issue":"5","key":"1395_CR29","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3322\/caac.21150","volume":"62","author":"AV Bennett","year":"2012","unstructured":"Bennett AV, Jensen RE, Basch E (2012) Electronic patient-reported outcome systems in oncology clinical practice. CA Cancer J Clin 62(5):336\u2013347","journal-title":"CA Cancer J. Clin."}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-018-1395-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00066-018-1395-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-018-1395-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T19:13:43Z","timestamp":1573067623000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00066-018-1395-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,7]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["1395"],"URL":"https:\/\/doi.org\/10.1007\/s00066-018-1395-y","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,7]]},"assertion":[{"value":"5 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.\u00a0Rammant, P.\u00a0Ost, M.\u00a0Swimberghe, B.\u00a0Vanderstraeten, N.\u00a0Lumen, K.\u00a0Decaestecker, R.\u00a0Bultijnck, G.\u00a0De Meerleer, C.\u00a0Sarrazyn, R.\u00a0Colman, and V.\u00a0Fonteyne declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}